Close Menu

mergers & acquisitions

Labindia had been a distributor of Applied Biosystems products since 1994.

The deal was abandoned after the two companies could not reach new terms and conditions following a Medicare contractor's decision to cover only one of RedPath's tests.

A GE Healthcare executive believes the firm can build a "$1billion-plus business by developing integrated diagnostic solutions for cancer and other diseases."

According to MorphoSys, the deal will allow it to improve the success rate for new antibody drug candidate development to the point where 50 percent of new projects will reach clinical development.

The newly created HDS will provide oncology translational research services, such as drug profiling, novel 2D and 3D phenotypic assays, tumor microenvironment studies, and responsive-patient prediction.

The total deal value could reach $725 million if certain milestones are met.

The merger with Genpoint, which NorDiag acquired three years ago, was done to reduce expenses to both firms.

LabCorp will purchase the Genetics segment in its entirety, including all testing services, technology, intellectual property rights, and its nine testing laboratories and offer employment to all of its 1,900 employees.

The firms will combine Biosystems International's monoclonal antibody proteomics process with MBC's microarray technology.

Upon completion of the acquisition, the combined company's focus will be strictly on Lumigene's business of developing diagnostics using its nucleic acid amplification platform.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.